Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Standard Biotools Inc (LAB)

Standard Biotools Inc (LAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 392,256
  • Shares Outstanding, K 384,565
  • Annual Sales, $ 85,330 K
  • Annual Income, $ -74,900 K
  • EBIT $ -92 M
  • EBITDA $ -166 M
  • 60-Month Beta 1.36
  • Price/Sales 4.78
  • Price/Cash Flow N/A
  • Price/Book 1.01
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.12
  • Most Recent Earnings $-0.04 on 11/04/25
  • Next Earnings Date 05/05/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical Information Systems

Options Overview Details

View History
  • Implied Volatility 372.30% (-95.30%)
  • Historical Volatility 39.95%
  • IV Percentile 79%
  • IV Rank 54.67%
  • IV High 664.41% on 04/08/25
  • IV Low 20.04% on 09/04/25
  • Expected Move (DTE 14) 0.1700 (17.17%)
  • Put/Call Vol Ratio 0.80
  • Today's Volume 27
  • Volume Avg (30-Day) 201
  • Put/Call OI Ratio 0.22
  • Today's Open Interest 1,692
  • Open Int (30-Day) 2,195
  • Expected Range 0.8202 to 1.1602

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.04
  • Number of Estimates 1
  • High Estimate -0.04
  • Low Estimate -0.04
  • Prior Year -0.06
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9700 +2.08%
on 03/06/26
1.2800 -22.64%
on 02/10/26
-0.2698 (-21.41%)
since 02/06/26
3-Month
0.9700 +2.08%
on 03/06/26
1.7200 -42.43%
on 12/22/25
-0.4398 (-30.76%)
since 12/05/25
52-Week
0.9200 +7.63%
on 05/23/25
1.7200 -42.43%
on 12/22/25
-0.1398 (-12.37%)
since 03/06/25

Most Recent Stories

More News
Standard BioTools: Q4 Earnings Snapshot

Standard BioTools: Q4 Earnings Snapshot

LAB : 0.9902 (-2.92%)
Standard BioTools Reports Fourth Quarter and Full Year 2025 Financial Results

BOSTON, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter and fiscal year...

LAB : 0.9902 (-2.92%)
Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

BOSTON, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish fourth quarter and full year 2025 financial results on Tuesday, February 24,...

LAB : 0.9902 (-2.92%)
Standard BioTools Completes Sale of SomaLogic to Illumina

Received $350 Million in upfront cash at closing; Up to $425 Million in total proceeds inclusive of near-term earnout payments Approximately $550 Million in cash & cash equivalents on balance sheet...

ILMN : 124.62 (-2.82%)
LAB : 0.9902 (-2.92%)
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue

BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced preliminary and unaudited revenue results for the fourth...

LAB : 0.9902 (-2.92%)
Molecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass Cytometry

Advancing next-generation IMC workflows with class-leading HCR imaging technologies for greater sensitivity and flexibility

LAB : 0.9902 (-2.92%)
Illumina® Protein Prep delivers groundbreaking precision in NGS proteomics for more than 40 customers, ranging from academic institutions to large national biobanks

Following global commercial launch in September, Illumina Protein Prep's "out of the box" solution drives extraordinary accessibility to proteomics for researchers, with over 40,000 samples processed

ILMN : 124.62 (-2.82%)
LAB : 0.9902 (-2.92%)
Standard BioTools: Q3 Earnings Snapshot

Standard BioTools: Q3 Earnings Snapshot

LAB : 0.9902 (-2.92%)
Standard BioTools Reports Third Quarter 2025 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended...

LAB : 0.9902 (-2.92%)
Standard BioTools to Announce Third Quarter Financial Results on November 4, 2025

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish third quarter 2025 financial results on Tuesday, November 4, 2025,...

LAB : 0.9902 (-2.92%)

Business Summary

Standard BioTools Inc. is a solution provider in health and disease using its proprietary mass cytometry and microfluidics technologies. It serves academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories. Standard BioTools Inc., formerly known as Fluidigm...

See More

Key Turning Points

3rd Resistance Point 1.1001
2nd Resistance Point 1.0701
1st Resistance Point 1.0301
Last Price 0.9902
1st Support Level 0.9601
2nd Support Level 0.9301
3rd Support Level 0.8901

See More

52-Week High 1.7200
Fibonacci 61.8% 1.4144
Fibonacci 50% 1.3200
Fibonacci 38.2% 1.2256
Last Price 0.9902
52-Week Low 0.9200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar